tetano
Editor, Senior Moderator
Infez Med
. 2021 Dec 10;29(4):495-503.
doi: 10.53854/liim-2904-1. eCollection 2021.
Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: A narrative review
Thoyaja Koritala[SUP] 1 [/SUP], Vishwanath Pattan[SUP] 2 [/SUP], Raghavendra Tirupathi[SUP] 3 [/SUP], Ali A Rabaan[SUP] 4 5 [/SUP], Abbas Al Mutair[SUP] 6 7 8 [/SUP], Saad Alhumaid[SUP] 9 [/SUP], Ramesh Adhikari[SUP] 10 [/SUP], Keerti Deepika[SUP] 11 [/SUP], Nitesh Kumar Jain[SUP] 12 [/SUP], Vikas Bansal[SUP] 13 [/SUP], Aysun Tekin[SUP] 13 [/SUP], Simon Zec[SUP] 13 [/SUP], Amos Lal[SUP] 14 [/SUP], Syed Anjum Khan[SUP] 12 [/SUP], Juan Pablo Domecq Garces[SUP] 15 [/SUP], Omar M Abu Saleh[SUP] 16 [/SUP], Salim R Surani[SUP] 17 18 [/SUP], Rahul Kashyap[SUP] 19 [/SUP]
Affiliations
Abstract
Introduction: To date, only corticosteroids and interleukin-6 (IL-6) inhibitors have been shown to reduce mortality of hospitalized patients with COVID-19. In this literature review, we aimed to summarize infection risk of IL inhibitors, with or without the use of corticosteroids, used to treat hospitalized patients with COVID-19.
Methods: A literature search was conducted using the following evidence-based medicine reviews: Cochrane Central Register of Controlled Trials; Cochrane Database of Systematic Reviews; Embase; Ovid Medline; and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions 1946 to April 28, 2021. All relevant articles were identified using the search terms COVID-19 or SARS-coronavirus-2, infections, interleukins, inpatients, adults, and i ncidence.
Results: We identified 36 studies of which 2 were meta-analyses, 5 were randomized controlled trials, 9 were prospective studies, and 20 were retrospective studies. When anakinra was compared with control, 2 studies reported an increased risk of infection, and 3 studies reported a similar or decreased incidence of infection. Canakinumab had a lower associated incidence of infection compared with placebo in one study. When sarilumab was compared with placebo, one study reported an increased risk of infection. Nine studies comparing tocilizumab with placebo reported decreased or no difference in infection risk (odds ratio [OR] for the studies ranged from 0.39-1.21). Fourteen studies comparing tocilizumab with placebo reported an increased risk of infection, ranging from 9.1% to 63.0% (OR for the studies ranged from 1.85-5.04). Infection most commonly presented as bacteremia. Of the 6 studies comparing tocilizumab and corticosteroid use with placebo, 4 reported a nonsignificant increase toward corticosteroids being associated with bacterial infections (OR ranged from 2.76-3.8), and 2 studies reported no increased association with a higher infection risk.
Conclusions: Our literature review showed mixed results with variable significance for the association of IL-6 inhibitors with risk of infections in patients with COVID-19.
Keywords: COVID-19; Corticosteroid; cytokine storm; infection; interleukin inhibitor.
. 2021 Dec 10;29(4):495-503.
doi: 10.53854/liim-2904-1. eCollection 2021.
Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: A narrative review
Thoyaja Koritala[SUP] 1 [/SUP], Vishwanath Pattan[SUP] 2 [/SUP], Raghavendra Tirupathi[SUP] 3 [/SUP], Ali A Rabaan[SUP] 4 5 [/SUP], Abbas Al Mutair[SUP] 6 7 8 [/SUP], Saad Alhumaid[SUP] 9 [/SUP], Ramesh Adhikari[SUP] 10 [/SUP], Keerti Deepika[SUP] 11 [/SUP], Nitesh Kumar Jain[SUP] 12 [/SUP], Vikas Bansal[SUP] 13 [/SUP], Aysun Tekin[SUP] 13 [/SUP], Simon Zec[SUP] 13 [/SUP], Amos Lal[SUP] 14 [/SUP], Syed Anjum Khan[SUP] 12 [/SUP], Juan Pablo Domecq Garces[SUP] 15 [/SUP], Omar M Abu Saleh[SUP] 16 [/SUP], Salim R Surani[SUP] 17 18 [/SUP], Rahul Kashyap[SUP] 19 [/SUP]
Affiliations
- PMID: 35146357
- PMCID: PMC8805476
- DOI: 10.53854/liim-2904-1
Abstract
Introduction: To date, only corticosteroids and interleukin-6 (IL-6) inhibitors have been shown to reduce mortality of hospitalized patients with COVID-19. In this literature review, we aimed to summarize infection risk of IL inhibitors, with or without the use of corticosteroids, used to treat hospitalized patients with COVID-19.
Methods: A literature search was conducted using the following evidence-based medicine reviews: Cochrane Central Register of Controlled Trials; Cochrane Database of Systematic Reviews; Embase; Ovid Medline; and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions 1946 to April 28, 2021. All relevant articles were identified using the search terms COVID-19 or SARS-coronavirus-2, infections, interleukins, inpatients, adults, and i ncidence.
Results: We identified 36 studies of which 2 were meta-analyses, 5 were randomized controlled trials, 9 were prospective studies, and 20 were retrospective studies. When anakinra was compared with control, 2 studies reported an increased risk of infection, and 3 studies reported a similar or decreased incidence of infection. Canakinumab had a lower associated incidence of infection compared with placebo in one study. When sarilumab was compared with placebo, one study reported an increased risk of infection. Nine studies comparing tocilizumab with placebo reported decreased or no difference in infection risk (odds ratio [OR] for the studies ranged from 0.39-1.21). Fourteen studies comparing tocilizumab with placebo reported an increased risk of infection, ranging from 9.1% to 63.0% (OR for the studies ranged from 1.85-5.04). Infection most commonly presented as bacteremia. Of the 6 studies comparing tocilizumab and corticosteroid use with placebo, 4 reported a nonsignificant increase toward corticosteroids being associated with bacterial infections (OR ranged from 2.76-3.8), and 2 studies reported no increased association with a higher infection risk.
Conclusions: Our literature review showed mixed results with variable significance for the association of IL-6 inhibitors with risk of infections in patients with COVID-19.
Keywords: COVID-19; Corticosteroid; cytokine storm; infection; interleukin inhibitor.